Affinivaxincwas A Clinical Stagebiopharmaceutical Company Based In Cambridgemassachusettsfocused On Innovativevaccinedevelopmentfounded In 2014Thecompany Specialized In Addressing Antimicrobial Resistanceand Novel Pathogens Using Its Proprietary Mapsa Cmultipleantigen Presenting Systemtechnologythis Platform Allowed For Thedesign Of Vaccines That Target Both Polysaccharides And Proteinsleading To Broad Immuneresponsesaffinivax Was Acquired By Gsk In August 2022 For $2 1 Billionwith Additional Milestonepayments Possiblethecompany S Lead Candidateafx 772Was A 24 Valent Pneumococcal Vaccinein Phaseii Trialsaimed At Providing Broader Serotypecoveragethan Existing Optionsaffinivax Also Had A 0 Plus Valent Pneumococcal Candidatein Preclinical Developmentfollowing Theacquisitionaffinivax S Operations And Pipelinewereintegrated Into Gskaes Vaccines Portfoliofocusing On Advancing Mapsa C Based Vaccines And Enhancing Gsk S Presencein Theboston Biotech Sector
